Merck's Keytruda Hits Main Endpoint in Stomach Cancer Study
November 23 2022 - 1:44AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Tuesday said a Phase 3 study of its
blockbuster cancer drug Keytruda met its key endpoint in certain
patients with stomach cancer.
The Kenilworth, N.J., drugmaker said Keytruda combined with
chemotherapy showed a statistically significant and clinically
meaningful improvement in the study's primary endpoint of overall
survival versus chemotherapy alone as the first-line treatment of
patients with human epidermal growth factor receptor 2, or HER2,
negative locally advanced unresectable or metastatic gastric or
gastroesophageal junction adenocarcinoma.
Merck said it also saw statistically significant and clinically
meaningful improvements in progression-free survival and overall
response rate.
Keytruda, a cancer drug that harnesses a patient's immune system
to fight tumors, is approved in dozens of indications around the
world and had sales of nearly $15.5 billion for the first nine
months of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 22, 2022 07:35 ET (12:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024